SCHEMBL4083523

SCHEMBL4083523

COc1ccc2cc(-c3n[nH]c4ccc(-c5n[nH]c(CC(C)C)n5)cc34)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.44
ADORA2A P29274 6/20 0.42
ADORA1 P30542 4/20 0.42
TTK P33981 2/20 0.42
ITK Q08881 5/20 0.42
PRKAG1 P54619 1/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKAB1 Q9Y478 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
CCNB2 O95067 1/20 0.40
ABL1 P00519 1/20 0.40
CDK1 P06493 1/20 0.40
PDGFRB P09619 1/20 0.40
CDK4 P11802 1/20 0.40
SRC P12931 1/20 0.40
CCNB1 P14635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5380077 0.91 ADORA2A (0.53) CSNK1DADORA2AADORA1TTKROCK2
SCHEMBL5387119 0.87 CSNK1D (0.45) CSNK1DPLK4CDK1CDK4CCNA2
SCHEMBL4094138 0.85 BRAF (0.42) CSNK1DTTKFLT3LRRK2
SCHEMBL5372615 0.85 CSNK1D (0.54) CSNK1DADORA2AADORA1TTKITK
SCHEMBL13812057 0.85 ACHE (0.39) CSNK1DADORA2AADORA1TTKLRRK2
SCHEMBL5383779 0.84 CSNK1D (0.43) CSNK1DADORA2AADORA1PLK4CDK1
SCHEMBL4094402 0.84 FGFR4 (0.43) CSNK1DTTKNPC1RAB9A
SCHEMBL5393207 0.83 CSNK1D (0.47) CSNK1DADORA2AADORA1NPC1RAB9A
SCHEMBL5373485 0.83 CSNK1D (0.48) CSNK1DTTKRAB9APLK4CDK1
SCHEMBL4089558 0.82 ROCK2 (0.46) CSNK1DADORA2AADORA1TTKITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CSNK1D 702/4885ADORA2A 1535/4885ADORA1 1429/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CSNK1D 687/4885ADORA2A 1577/4885ADORA1 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.